Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15289259 | 1.00 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL15289245 | 1.00 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL13515005 | 1.00 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL19072374 | 1.00 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL8306284 | 1.00 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL24621364 | 1.00 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL19011990 | 0.78 | — | — | |
| SCHEMBL19011994 | 0.78 | — | — | |
| SCHEMBL19903645 | 0.78 | — | — | |
| SCHEMBL19011989 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-25 | — | — | US | disclosed |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| WO-2009140111-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | EPHX1 4663/4885 |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | EPHX1 4663/4885 |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | JAK3, JAK2, JAK1 | EPHX1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.